<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38385713</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-1594</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Artificial organs</Title><ISOAbbreviation>Artif Organs</ISOAbbreviation></Journal><ArticleTitle>Cost-effective 3D lung tissue spheroid as a model for SARS-CoV-2 infection and drug screening.</ArticleTitle><Pagination><StartPage>723</StartPage><EndPage>733</EndPage><MedlinePgn>723-733</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/aor.14729</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The SARS-CoV-2 pandemic has spurred an unparalleled scientific endeavor to elucidate the virus' structure, infection mechanisms, and pathogenesis. Two-dimensional culture systems have been instrumental in shedding light on numerous aspects of COVID-19. However, these in&#xa0;vitro systems lack the physiological complexity to comprehend the infection process and explore treatment options. Three-dimensional (3D) models have been proposed to fill the gap between 2D cultures and in&#xa0;vivo studies. Specifically, spheroids, composed of lung cell types, have been suggested for studying SARS-CoV-2 infection and serving as a drug screening platform.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">3D lung spheroids were prepared by coculturing human alveolar or bronchial epithelial cells with human lung stromal cells. The morphology, size, and ultrastructure of spheroids before and after SARS-CoV-2 infection were analyzed using optical and electron microscopy. Immunohistochemistry was used to detect spike protein and, thus, the virus presence in the spheroids. Multiplex analysis elucidated the cytokine release after virus infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The spheroids were stable and kept their size and morphology after SARS-CoV-2 infection despite the presence of multivesicular bodies, endoplasmic reticulum rearrangement, tubular compartment-enclosed vesicles, and the accumulation of viral particles. The spheroid responded to the infection releasing IL-6 and IL-8 cytokines.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrates that coculture spheroids of epithelial and stromal cells can serve as a cost-effective infection model for the SARS-CoV-2 virus. We suggest using this 3D spheroid as a drug screening platform to explore new treatments related to the cytokines released during virus infection, especially for long COVID treatment.</AbstractText><CopyrightInformation>&#xa9; 2024 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Guilherme A S C</ForeName><Initials>GASC</Initials><AffiliationInfo><Affiliation>Gcell 3D, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corr&#xea;a</LastName><ForeName>Isadora Alonso</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica e Imunologia das Infec&#xe7;&#xf5;es Virais, Departamento de Virologia, Instituto de Microbiologia Paulo de G&#xf3;es, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amorim</LastName><ForeName>&#xc9;rica Almeida</ForeName><Initials>&#xc9;A</Initials><AffiliationInfo><Affiliation>Gcell 3D, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Ultraestrutura celular Hertha Meyer, Centro de Pesquisa em Medicina de Precis&#xe3;o, Instituto de Biof&#xed;sica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caldas</LastName><ForeName>Lucio Ayres</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Ultraestrutura celular Hertha Meyer, Centro de Pesquisa em Medicina de Precis&#xe3;o, Instituto de Biof&#xed;sica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>N&#xfa;cleo Multidisciplinar de Pesquisa (Numpex-bio), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carneiro</LastName><ForeName>Fabiana &#xc1;vila</ForeName><Initials>F&#xc1;</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Ultraestrutura celular Hertha Meyer, Centro de Pesquisa em Medicina de Precis&#xe3;o, Instituto de Biof&#xed;sica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>N&#xfa;cleo Multidisciplinar de Pesquisa (Numpex-bio), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Costa</LastName><ForeName>Luciana Jesus</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica e Imunologia das Infec&#xe7;&#xf5;es Virais, Departamento de Virologia, Instituto de Microbiologia Paulo de G&#xf3;es, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granjeiro</LastName><ForeName>Jos&#xe9; Mauro</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Biologia de C&#xe9;lulas Eucari&#xf3;ticas, Duque de Caxias, Instituto Nacional de Metrologia, Qualidade e Tecnologia, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Pesquisa Cl&#xed;nica em Odontologia, Universidade Federal Fluminense, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanuri</LastName><ForeName>Amilcar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica e Imunologia das Infec&#xe7;&#xf5;es Virais, Departamento de Virologia, Instituto de Microbiologia Paulo de G&#xf3;es, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Wanderley</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Ultraestrutura celular Hertha Meyer, Centro de Pesquisa em Medicina de Precis&#xe3;o, Instituto de Biof&#xed;sica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Nacional de Biologia Estrutural e Bioimagem, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baptista</LastName><ForeName>Leandra Santos</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>N&#xfa;cleo Multidisciplinar de Pesquisa (Numpex-bio), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Biologia de C&#xe9;lulas Eucari&#xf3;ticas, Duque de Caxias, Instituto Nacional de Metrologia, Qualidade e Tecnologia, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Financiadora de Estudos e Projetos</Agency><Country/></Grant><Grant><Agency>Funda&#xe7;&#xe3;o Carlos Chagas Filho de Amparo &#xe0; Pesquisa do Estado do Rio de Janeiro</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Artif Organs</MedlineTA><NlmUniqueID>7802778</NlmUniqueID><ISSNLinking>0160-564X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018874" MajorTopicYN="Y">Spheroids, Cellular</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="Y">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="Y">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3D in&#xa0;vitro model</Keyword><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2</Keyword><Keyword MajorTopicYN="N">drug screening</Keyword><Keyword MajorTopicYN="N">infection model</Keyword><Keyword MajorTopicYN="N">spheroids</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>11</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>22</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>22</Day><Hour>9</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38385713</ArticleId><ArticleId IdType="doi">10.1111/aor.14729</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Timeline: WHO's COVID&#x2010;19 Response [Internet]. Available from: https://www.who.int/emergencies/diseases/novel&#x2010;coronavirus&#x2010;2019/interactive&#x2010;timeline</Citation></Reference><Reference><Citation>World Health Organization (WHO). Therapeutics and COVID&#x2010;19&#x2014;Living Guideline [Internet]. 2021. Available from: https://apps.who.int/iris/bitstream/handle/10665/345356/WHO&#x2010;2019&#x2010;nCoV&#x2010;therapeutics&#x2010;2021.3&#x2010;eng.pdf?sequence=1&amp;isAllowed=y</Citation></Reference><Reference><Citation>Coronavirus Disease (COVID&#x2010;19) Pandemic [Internet]. Available from: https://www.who.int/europe/emergencies/situations/covid&#x2010;19</Citation></Reference><Reference><Citation>Salgado&#x2010;Benvindo C, Thaler M, Tas A, Ogando NS, Bredenbeek PJ, Ninaber DK, et&#xa0;al. Suramin inhibits SARS&#x2010;CoV&#x2010;2 infection in cell culture by interfering with early steps of the replication cycle. Antimicrob Agents Chemother. 2020 Jul 22;64(8):e00900&#x2010;20.</Citation></Reference><Reference><Citation>Tang WF, Tsai HP, Chang YH, Chang TY, Hsieh CF, Lin CY, et&#xa0;al. Perilla (Perilla frutescens) leaf extract inhibits SARS&#x2010;CoV&#x2010;2 via direct virus inactivation. Biom J. 2021 Jun;44(3):293&#x2013;303.</Citation></Reference><Reference><Citation>Gro&#xdf;e M, Setz C, Rauch P, Auth J, Morokutti&#x2010;Kurz M, Temchura V, et&#xa0;al. Inhibitors of deubiquitinating enzymes interfere with the SARS&#x2010;CoV&#x2010;2 papain&#x2010;like protease and block virus replication in&#xa0;vitro. Viruses. 2022 Jun 27;14(7):1404.</Citation></Reference><Reference><Citation>Murgolo N, Therien AG, Howell B, Klein D, Koeplinger K, Lieberman LA, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 tropism, entry, replication, and propagation: considerations for drug discovery and development. PLoS Pathog. 2021 Feb 17;17(2):e1009225.</Citation></Reference><Reference><Citation>Lamers MM, Haagmans BL. SARS&#x2010;CoV&#x2010;2 pathogenesis. Nat Rev Microbiol. 2022 May;20(5):270&#x2013;284.</Citation></Reference><Reference><Citation>de Melo BAG, Benincasa JC, Cruz EM, Maricato JT, Porcionatto MA. 3D culture models to study SARS&#x2010;CoV&#x2010;2 infectivity and antiviral candidates: from spheroids to bioprinting. Biom J. 2021 Feb;44(1):31&#x2013;42.</Citation></Reference><Reference><Citation>Do T, Synan L, Ali G, Gappa&#x2010;Fahlenkamp H. 3D tissue&#x2010;engineered lung models to study immune responses following viral infections of the small airways. Stem Cell Res Ther. 2022 Sep 7;13(1):464.</Citation></Reference><Reference><Citation>Fang Y, Eglen RM. Three&#x2010;dimensional cell cultures in drug discovery and development. SLAS Discov. 2017;22(5):456&#x2013;472.</Citation></Reference><Reference><Citation>Kronemberger GS, Carneiro FA, Rezende DF, Baptista LS. Spheroids and organoids as humanized 3D scaffold&#x2010;free engineered tissues for SARS&#x2010;CoV&#x2010;2 viral infection and drug screening. Artif Organs. 2021;45(6):548&#x2013;558.</Citation></Reference><Reference><Citation>Szlachcic WJ, Dabrowska A, Milewska A, Ziojla N, Blaszczyk K, Barreto&#x2010;Duran E, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 infects an in&#xa0;vitro model of the human developing pancreas through endocytosis. iScience. 2022 Jul;25(7):104594.</Citation></Reference><Reference><Citation>Higashi&#x2010;Kuwata N, Yabe SG, Fukuda S, Nishida J, Tamura&#x2010;Nakano M, Hattori S, et&#xa0;al. Generation of angiotensin&#x2010;converting enzyme 2/transmembrane protease serine 2&#x2010;double&#x2010;positive human induced pluripotent stem cell&#x2010;derived spheroids for anti&#x2010;severe acute respiratory syndrome coronavirus 2 drug evaluation. Microbiol Spectr. 2022 Dec 21;10(6):e03490&#x2010;22.</Citation></Reference><Reference><Citation>Amendola A, Garoffolo G, Songia P, Nardacci R, Ferrari S, Bernava G, et&#xa0;al. Human cardiosphere&#x2010;derived stromal cells exposed to SARS&#x2010;CoV&#x2010;2 evolve into hyper&#x2010;inflammatory/pro &#x2010;fibrotic phenotype and produce infective viral particles depending on the levels of ACE2 receptor expression. Cardiovasc Res. 2021 May 25;117(6):1557&#x2013;1566.</Citation></Reference><Reference><Citation>Omer D, Pleniceanu O, Gnatek Y, Namestnikov M, Cohen&#x2010;Zontag O, Goldberg S, et&#xa0;al. Human kidney spheroids and monolayers provide insights into SARS&#x2010;CoV&#x2010;2 renal interactions. JASN. 2021 Sep;32(9):2242&#x2013;2254.</Citation></Reference><Reference><Citation>Composi&#xe7;&#xe3;o contendo esfer&#xf3;ides, m&#xe9;todo para sua obten&#xe7;&#xe3;o e uso como modelo experimental. BR 10 2022 014637 3; 2022.</Citation></Reference><Reference><Citation>Gotoh S, Ito I, Nagasaki T, Yamamoto Y, Konishi S, Korogi Y, et&#xa0;al. Generation of alveolar epithelial spheroids via isolated progenitor cells from human pluripotent stem cells. Stem Cell Rep. 2014 Sep;3(3):394&#x2013;403.</Citation></Reference><Reference><Citation>Henry E, Cores J, Hensley MT, Anthony S, Vandergriff A, de Andrade JBM, et&#xa0;al. Adult lung spheroid cells contain progenitor cells and mediate regeneration in rodents with bleomycin&#x2010;induced pulmonary fibrosis. Stem Cells Transl Med. 2015 Nov;4(11):1265&#x2013;1274.</Citation></Reference><Reference><Citation>Dinh PUC, Cores J, Hensley MT, Vandergriff AC, Tang J, Allen TA, et&#xa0;al. Derivation of therapeutic lung spheroid cells from minimally invasive transbronchial pulmonary biopsies. Respir Res. 2017 Jun 30;18(1):132.</Citation></Reference><Reference><Citation>Flagg M, Goldin K, P&#xe9;rez&#x2010;P&#xe9;rez L, Singh M, Williamson BN, Pruett N, et&#xa0;al. Low level of tonic interferon signalling is associated with enhanced susceptibility to SARS&#x2010;CoV&#x2010;2 variants of concern in human lung organoids. Emerg Microbes Infect. 2023 Dec;12(2):2276338.</Citation></Reference><Reference><Citation>Moreira A, M&#xfc;ller M, Costa PF, Kohl Y. Advanced in&#xa0;vitro lung models for drug and toxicity screening: the promising role of induced pluripotent stem cells. Adv Biol. 2022 Feb;6(2):2101139.</Citation></Reference><Reference><Citation>Konishi S, Gotoh S, Tateishi K, Yamamoto Y, Korogi Y, Nagasaki T, et&#xa0;al. Directed induction of functional multi&#x2010;ciliated cells in proximal airway epithelial spheroids from human pluripotent stem cells. Stem Cell Rep. 2016 Jan;6(1):18&#x2013;25.</Citation></Reference><Reference><Citation>Saleh F, Harb A, Soudani N, Zaraket H. A three&#x2010;dimensional A549 cell culture model to study respiratory syncytial virus infections. J Infect Public Health. 2020 Aug;13(8):1142&#x2013;1147.</Citation></Reference><Reference><Citation>Park BK, Kim D, Park S, Maharjan S, Kim J, Choi JK, et&#xa0;al. Differential signaling and virus production in Calu&#x2010;3 cells and vero cells upon SARS&#x2010;CoV&#x2010;2 infection. Biomol Ther (Seoul). 2021 May 1;29(3):273&#x2013;281.</Citation></Reference><Reference><Citation>Franzd&#xf3;ttir SR, Axelsson IT, Arason AJ, Baldursson &#xd3;, Gudjonsson T, Magnusson MK. Airway branching morphogenesis in three dimensional culture. Respir Res. 2010 Nov 25;11(1):162.</Citation></Reference><Reference><Citation>Gupta G, Vallabani S, Bordes R, Bhattacharya K, Fadeel B. Development of microfluidic, serum&#x2010;free bronchial epithelial cells&#x2010;on&#x2010;a&#x2010;Chip to facilitate a more realistic in&#xa0;vitro testing of nanoplastics. Front Toxicol [Internet]. 2021 [cited 2023 Jun 16];3:735331. https://doi.org/10.3389/ftox.2021.735331</Citation></Reference><Reference><Citation>Powers KA, Dhamoon AS. Physiology, pulmonary ventilation and perfusion. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Jun 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK539907/</Citation></Reference><Reference><Citation>Chimenti I, Pagano F, Angelini F, Siciliano C, Mangino G, Picchio V, et&#xa0;al. Human lung spheroids as in&#xa0;vitro niches of lung progenitor cells with distinctive paracrine and plasticity properties. Stem Cells Transl Med. 2017 Mar 1;6(3):767&#x2013;777.</Citation></Reference><Reference><Citation>Deinhardt&#x2010;Emmer S, B&#xf6;ttcher S, H&#xe4;ring C, Giebeler L, Henke A, Zell R, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 causes severe epithelial inflammation and barrier dysfunction. J Virol. 2021 Apr 26;95(10):e00110&#x2010;21. https://doi.org/10.1128/jvi.00110&#x2010;21</Citation></Reference><Reference><Citation>Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, et&#xa0;al. SARS&#x2010;CoV&#x2010;2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020 May 18;39(10):e105114.</Citation></Reference><Reference><Citation>Knoops K, Kikkert M, van den Worm SHE, Zevenhoven&#x2010;Dobbe JC, van der Meer Y, Koster AJ, et&#xa0;al. SARS&#x2010;coronavirus replication is supported by a Reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 2008 Sep 16;6(9):e226.</Citation></Reference><Reference><Citation>Caldas LA, Carneiro FA, Monteiro FL, Augusto I, Higa LM, Miranda K, et&#xa0;al. Intracellular host cell membrane remodelling induced by SARS&#x2010;CoV&#x2010;2 infection in&#xa0;vitro. Biol Cell. 2021 Jun;113(6):281&#x2013;293.</Citation></Reference><Reference><Citation>Mendon&#xe7;a L, Howe A, Gilchrist JB, Sheng Y, Sun D, Knight ML, et&#xa0;al. Correlative multi&#x2010;scale cryo&#x2010;imaging unveils SARS&#x2010;CoV&#x2010;2 assembly and egress. Nat Commun. 2021 Jul 30;12(1):4629.</Citation></Reference><Reference><Citation>Ebisudani T, Sugimoto S, Haga K, Mitsuishi A, Takai&#x2010;Todaka R, Fujii M, et&#xa0;al. Direct derivation of human alveolospheres for SARS&#x2010;CoV&#x2010;2 infection modeling and drug screening. Cell Rep. 2021 Jun;35(10):109218.</Citation></Reference><Reference><Citation>da Silva SJR, do Nascimento JCF, Germano Mendes RP, Guarines KM, Targino Alves da Silva C, da Silva PG, et&#xa0;al. Two years into the COVID&#x2010;19 pandemic: lessons learned. ACS Infect Dis. 2022 Sep 9;8(9):1758&#x2013;1814.</Citation></Reference><Reference><Citation>Hasanvand A. COVID&#x2010;19 and the role of cytokines in this disease. Inflammopharmacol. 2022 Jun;30(3):789&#x2013;798.</Citation></Reference><Reference><Citation>Queiroz MAF, das Neves PFM, Lima SS, da Costa Lopes J, da Silva Torres MK, Vallinoto IMVC, et&#xa0;al. Cytokine profiles associated with acute COVID&#x2010;19 and long COVID&#x2010;19 syndrome. Front Cell Infect Microbiol. 2022 Jun 30;12:922422.</Citation></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, et&#xa0;al. The IL&#x2010;1&#x3b2;, IL&#x2010;6, and TNF cytokine triad is associated with post&#x2010;acute sequelae of COVID&#x2010;19. Cell Rep Med. 2022 Jun 21;3(6):100663.</Citation></Reference><Reference><Citation>Zeraatkar D, Cusano E, Mart&#xed;nez JPD, Qasim A, Mangala S, Kum E, et&#xa0;al. Use of tocilizumab and sarilumab alone or in combination with corticosteroids for COVID&#x2010;19: systematic review and network meta&#x2010;analysis. BMJ Med. 2022 Mar 1;1(1):e000036.</Citation></Reference><Reference><Citation>Teijeira A, Migueliz I, Garasa S, Karanikas V, Luri C, Cirella A, et&#xa0;al. Three&#x2010;dimensional colon cancer organoids model the response to CEA&#x2010;CD3 T&#x2010;cell engagers. Theranostics. 2022 Jan 1;12(3):1373&#x2013;1387.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>